1 of 1
Story summary
- Eli Lilly and Company completed its acquisition of Ventyx Biosciences for $1.2 billion at $14 per share on January 7, 2026.
- The deal expands Lilly's immunology portfolio amid patent expirations on existing drugs.
- Ventyx specializes in oral therapies for Crohn's disease and rheumatoid arthritis, with promising candidates for obesity-related cardiovascular issues.
- Analysts view the price as manageable for Lilly, which has recently surpassed $1 trillion in market value.
